Merck Sharp & Dohme

Kenilworth, United States Founded: 1890 • Age: 136 yrs Acquired By Onyx Equities
Therapies for HIV, cancer, diabetes, and infectious diseases are developed.
Request Access

About Merck Sharp & Dohme

Merck Sharp & Dohme is a company based in Kenilworth (United States) founded in 1890 was acquired by Onyx Equities in February 2023.. Merck Sharp & Dohme has completed 2 acquisitions, including EyeBio and Merck. Merck Sharp & Dohme offers products and services including Vaccines, Medicines, and Clinical Trials. Merck Sharp & Dohme operates in a competitive market with competitors including Jazz Pharmaceuticals, C4 Therapeutics, Erasca, MiRagen and Mereo BioPharma, among others.

  • Headquarter Kenilworth, United States
  • Sectors
    Healthcare
  • Phone
    *********
  • Website
    *********
  • Social
    *********
  • Legal Name Merck & Co., Inc., Rahway, Nj, Usa
Operational Areas
Healthcare → Healthcare Products & Supplies
Healthcare → Healthcare Products & Supplies
Key Metrics
  • Annual Revenue
  • Net Profit
  • EBITDA
  • Latest Funding Round
    $12.03 K (USD), Grant

    Oct 01, 2019

  • Investors
  • Employee Count
    Employee Count
  • Investments & Acquisitions
    EyeBio

    & 1 more

  • Acquired by
    Onyx Equities

    (Feb 21, 2023)

Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • Full access to every database India & global coverage, advanced filters and rich profile details
  • Always-on access from your team account Single premium plan for everything you see on the portal

Products & Services of Merck Sharp & Dohme

Merck Sharp & Dohme offers a comprehensive portfolio of products and services, including Vaccines, Medicines, and Clinical Trials. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.

Primary

Products for preventing infectious diseases through immunization.

Treatments for conditions like oncology and immunology.

Platforms for testing new health solutions and innovations.

People of Merck Sharp & Dohme
Headcount 10000+
Employee Profiles 1236
Board Members and Advisors 12
Employee Profiles
People
Jacob Bordens
Senior Director, Enterprise Architecture
People
Kelley Brna
Vice President Operations
People
Christina Campellone
Executive Customer Representative- Chronic Care
People
Robert Tynebor
Director

Unlock access to complete

Board Members and Advisors
people
Inge G. Thulin
Director
people
Patricia F. Russo
Director
people
Paul B. Rothman
Director
people
Mary Ellen Coe
Member Board Of Directors

Unlock access to complete

Funding Insights of Merck Sharp & Dohme

  • Total Funding
  • Total Rounds 3
  • Last Round Grant — $12,030
  • First Round

    (01 Apr 2015)

  • Investors Count 1
Date Amount Transaction Name Valuation Lead Investors Investors
Oct, 2019 Amount Grant - Merck Sharp & Dohme Valuation

investors

Apr, 2017 Amount Grant - Merck Sharp & Dohme Valuation

investors

Apr, 2015 Amount Grant - Merck Sharp & Dohme Valuation

investors

Date Amount Transaction Name Valuation Lead Investors Investors
Jul, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Jan, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Investors in Merck Sharp & Dohme

Merck Sharp & Dohme has secured backing from 3 investors, including institutional investors. Prominent investors backing the company include European Union, Machine Investment Group and Onyx Equities. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.

All
Institutional
Investor Description Founded Year Domain Location
Government entites focused on freedom, democracy, equality and the rule of law, promoting peace and stability
Founded Year Domain Location
Invests in middle market real estate opportunities, distressed debt, and special situations.
Founded Year Domain Location
Acquires and manages under-performing commercial properties with full service platform.
Founded Year Domain Location
Investor Description Founded Year Domain Location
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
Founded Year Domain Location
Startup ecosystems are ignited through strategic investments by Signite Partners.
Founded Year Domain Location
Venture capital is directed toward companies in multiple sectors.
Founded Year Domain Location
Venture capital is invested in cybersecurity, fintech, and AI startups.
Founded Year Domain Location

Investments & Acquisitions by Merck Sharp & Dohme

Merck Sharp & Dohme has strategically engaged in corporate development activities, having acquired 2 companies. Notable acquisitions include EyeBio and Merck. These strategic investments and acquisitions demonstrate the company's commitment to growth through portfolio expansion, market consolidation, technology integration, and strategic partnerships that enhance competitive positioning and drive long-term value creation.

Investments
Company Name Description Domain Location Founded Year Amount
Bionic investment advisor platform
2016
Fine Asian gourmet food is offered by an internet-first restaurant.
2016
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
2014
Fine Asian gourmet food is offered by an internet-first restaurant.
2016
Acquisitions
Company Name Description Domain Location Founded Year Amount
Therapies for ophthalmological diseases are developed to restore vision.
2021
T-cell antibodies are developed against hematologic and solid tumor targets.
2015
Company Name Description Domain Location Founded Year Amount
OVO is recognized as a smart digital payment application.
2017
Bionic investment advisor platform
2016
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
2014
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
2014

Financial Statements - Merck Sharp Dohme

Tata Steel revenue growth over time
Tata Steel profit and loss trends over time
Date Amount Transaction Name Valuation Lead Investors Investors
Jul, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Jan, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Merck Sharp & Dohme Comparisons

Employees
+
Add Comparison
Available on Premium

Competitors of Merck Sharp & Dohme

Merck Sharp & Dohme operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Jazz Pharmaceuticals, C4 Therapeutics, Erasca, MiRagen and Mereo BioPharma, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.

Company Name Domain Founded year HQ Location Description
domain founded_year HQ Location
Novel biopharmaceutical medicines are developed for unmet medical needs.
domain founded_year HQ Location
Small-molecule drugs for cancer treatment are developed via Degronimid platform.
domain founded_year HQ Location
Small molecule therapeutics for cancer treatment are developed.
domain founded_year HQ Location
MicroRNA-based therapeutics are developed for treating multiple diseases.
domain founded_year HQ Location
Therapeutics for cancer and rare diseases are developed.
domain founded_year HQ Location
Targeted therapeutics for cancer, metabolic, and inflammatory diseases are developed.
Company Name Domain Founded year HQ Location Description
domain founded_year HQ Location
Multiple services are booked via an app-based platform.
domain founded_year HQ Location
On-demand services are booked through an app-based platform.
domain founded_year HQ Location
App based platform offering on demand delivery and ride-hailing services
domain founded_year HQ Location
Operates an on-demand hyperlocal delivery app for food and groceries.

Latest news on Merck Sharp & Dohme

Frequently Asked Questions about Merck Sharp & Dohme

When was Merck Sharp & Dohme founded?

Merck Sharp & Dohme was founded in 1890 and raised its 1st funding round 125 years after it was founded.

Where is Merck Sharp & Dohme located?

Merck Sharp & Dohme is headquartered in Kenilworth, United States.

What does Merck Sharp & Dohme do?

Merck Sharp Dohme was founded in 1890 and is headquartered in Kenilworth, United States. Operations focus on pharmaceutical development within the healthcare sector. A pipeline of therapies is maintained, including MK-1439A for HIV treatment, V184 vaccine for chikungunya virus, and V937 for breast cancer. Additional portfolios address diabetes, infectious diseases, and oncology, with research extending to various therapeutic areas.

Who are the top competitors of Merck Sharp & Dohme?

Merck Sharp & Dohme's top competitors include Jazz Pharmaceuticals, C4 Therapeutics and Erasca.

What products or services does Merck Sharp & Dohme offer?

Merck Sharp & Dohme offers Vaccines, Medicines, and Clinical Trials.

How many acquisitions has Merck Sharp & Dohme made?

Merck Sharp & Dohme has made 2 acquisitions, including EyeBio, and Merck.

Who are Merck Sharp & Dohme's investors?

Merck Sharp & Dohme has 3 investors. Key investors include European Union, Machine Investment Group, and Onyx Equities.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available